ClinicalTrials.gg
Not yet recruitingNCT07756593Updated Aug 10, 2026

Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

A Phase 1 interventional study of Sipuleucel-T and N803 in Prostate Cancer and Metastatic Prostate Cancer, sponsored by Washington University School of Medicine. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Washington University School of Medicine · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies in Prostatic Neoplasms by Washington University School of Medicine — 9 open to participants now, 11 under way, none of them phase 3. Prostatic Neoplasms · Washington University School of Medicine.

Planned enrollment
12th of 20
30 · median 35
Started
2026
with 4 others
Phase 1
4 of 23
1 open now
Primary completion
2029-04
later than 7 of 10 live
Registered
23rd of 23
by date

Among the 23 studies in Prostatic Neoplasms by Washington University School of Medicine, this one is the 12th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 7 of the 10 other live ones, and was the 23rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 23 studies in Prostatic Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

This phase Ib single-center open-label de-escalation study uses a modified 3+3 design to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination of standard of care Sip-T and N-803 in patients with metastatic androgen pathway modulation resistant (mAPMR) prostate cancer. Patients will receive treatment for up to 8 weeks.

03

Conditions studied

  • Prostate Cancer
  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Immunotherapy
  • Sipuleucel-T
  • IL-15
  • Metastatic Prostate Cancer
  • Cellular Therapy
  • Cytokine Therapy
  • Combination Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed prostate adenocarcinoma.
  • Imaging- or -proven disease. May have any type or location of metastases (bone, lymph node, visceral).
  • Prior treatment must include either orchiectomy or luteinizing hormone-releasing agonist or antagonist treatment with documented testosterone ≤ 50 ng/dL.
  • Eligible for standard of care Sipuleucel-T.
  • Recovery to baseline or ≤ grade 1 from toxicities related to any prior treatments, unless AEs are clinically nonsignificant and/or stable on supportive therapy.
  • At least 18 years of age.
  • performance status ≤ 2
  • Adequate bone marrow and organ function as defined below:

    • ≥ 1,500 K/cumm without granulocyte colony-stimulating factor support
    • ≥ 100,000 K/cumm without transfusion
    • ≥ 10.0 g/dL
    • Total ≤ 1.5 x IULN
    • (SGOT) and ALT(SGPT) ≤ 2.5 x IULN
    • Calculated ≥ 50 mL/min by Cockcroft-Gault
  • PSA ≤ 200 ng/mL.
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants

Exclusion criteria

Exclusion Criteria:

  • Rapidly progressing disease or symptomatic prostate cancer as assessed by the investigator.
  • Prior immunotherapy (e.g., , anti-PD-L1, anti-CTLA4) within the 6 months prior to enrollment.
  • Prior systemic radiotherapy (such as Ra-223, Lu177-PSMA) within the 6 months prior to enrollment. Prior palliative radiation therapy for bone within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment is allowed. Prior definitive radiation therapy for localized prostate cancer is allowed.
  • Prior exposure to Sipuleucel-T.
  • Ongoing systemic immune suppression (oral equivalent to 10 mg daily prednisone or less are allowed; topical, inhaled, and intra-articular steroids are allowed).
  • Currently receiving any other therapeutic or imaging agents.
  • Patients with known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or of brain metastasis). Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to Sipuleucel-T or N-803 or other agents used in the study.
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia. Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Function Classification; to be eligible for this trial, patients should be a class 2B or better.
  • -infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.
  • Evidence of chronic virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection.
  • History of virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection.
  • Uncontrolled infection with hepatitis A.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Dose level 0 Starting dose: N-803 + SIP-T

    Patients will receive standard dose (\>50 million CD54+ cells) subcutaneous (SC) SIP-T on Day 1, 15 and 29 and 15 mcg/kg SC dose of N-803 24 hours after SIP-T on Day 2, 16, and 30.

    Biological: Sipuleucel-T · Biological: N803

  • Experimental
    Cohort 1: Dose level -1: N-803 + SIP-T

    Patients will receive standard dose (\>50 million CD54+ cells) subcutaneous (SC) SIP-T on Day 1, 15 and 29 and 10 mcg/kg SC dose of N-803 24 hours after SIP-T on Day 2, 16, and 30.

    Biological: Sipuleucel-T · Biological: N803

  • Experimental
    Cohort 1: Dose level -2: N-803 + SIP-T

    Patients will receive standard dose (\>50 million CD54+ cells) subcutaneous (SC) SIP-T on Day 1, 15 and 29 and 6 mcg/kg SC dose of N-803 24 hours after SIP-T on Day 2, 16, and 30.

    Biological: Sipuleucel-T · Biological: N803

  • Experimental
    Cohort 2: N-803 + SIP-T

    Patients will receive standard dose (\>50 million CD54+ cells) subcutaneous (SC) SIP-T on Day 1, 15 and 29 and recommended phase 2 dose (RP2D) of N-803 24 hours after SIP-T on Day 2, 16, and 30. An additional dose of N-803 will occur on Day -5 or 5 days before first SIP-T dose.

    Biological: Sipuleucel-T · Biological: N803

  • Experimental
    Cohort 3: N-803 + SIP-T

    Patients will receive standard dose (\>50 million CD54+ cells) subcutaneous (SC) SIP-T on Day 1, 15 and 29 and RP2D of N-803 24 hours after SIP-T on Day 2, 16, and 30. An additional dose of N-803 will occur on Day 37.

    Biological: Sipuleucel-T · Biological: N803

Interventions

  • BiologicalSipuleucel-T

    Sipuleucel-T is a cellular therapeutic vaccine given in 3 complete doses at 2-week intervals intravenously.

    Also known as: Provenge, SipT

  • BiologicalN803

    N-803 is a biologic that is administered subcutaneously in the abdominal area.

06

What researchers measure

Primary outcomes

  1. Frequency of dose-limiting toxicities (Cohort 1 only)

    As assessed via CTCAE v6.0. Dose limiting toxicities will be evaluated according to protocol.

    Time frame: Start of treatment (day 1 dose of Sip-T) through 14 days following the last dose of N-803 (total time up to 44 days)

  2. Recommended Phase II Dose (RP2D) (Cohort 1 only)

    RP2D is defined as the highest dose of N-803 that has an overall DLT rate of less than 33% in total of 6 patients.

    Time frame: Start of treatment (day 1 dose of Sip-T) through 14 days following the last dose of N-803 for all participants in Cohort 1 (total time up to 44 days)

  3. Number of severe (grade 3+) adverse events measured via CTCAE v6.0

    Time frame: Start of treatment through 100 days after last dose of N-803 (total time up to 137 days)

  4. Number and type of adverse events measured via CTCAE v6.0

    Time frame: Start of treatment through 100 days after last dose of N-803 (total time up to 137 days)

Secondary outcomes

  1. PSA30 Response

    PSA response rate is defined as the proportion of subjects who have PSA response as defined by at least 30% reduction in PSA level from baseline measured twice at least 3 weeks apart. PSA response is measured per PCWG3 criteria.

    Time frame: Start of treatment to completion of follow-up (up to 26 months)

  2. PSA50 Response

    PSA response rate is defined as the proportion of subjects who have PSA response as defined by at least 50% reduction in PSA level from baseline measured twice at least 3 weeks apart. PSA response is measured per PCWG3 criteria.

    Time frame: Start of treatment to completion of follow-up (up to 26 months)

  3. PSA90 Response

    PSA response rate is defined as the proportion of subjects who have PSA response as defined by at least 90% reduction in PSA level from baseline measured twice at least 3 weeks apart. PSA response is measured per PCWG3 criteria.

    Time frame: Start of treatment to completion of follow-up (up to 26 months)

  4. Radiographic progression-free survival (PFS)

    rPFS is defined as the duration of time from start of treatment to time of radiographic progression by PCWG3 or time of death or last follow-up, the event that occurs first. Patients who have not experienced either event at the time of analysis will be censored at their last radiographic scan date. All radiographic response criteria are assessed per PCWG3 criteria.

    Time frame: Start of treatment to date of progression or death or last follow-up (up to 26 months)

  5. Failure-free survival (FFS)

    Failure-free survival which is defined from date of treatment start to date of any progression events (radiographic progression, biochemical recurrence, or death, whichever is earlier) or date of last follow-up if experiencing no events

    Time frame: Start of treatment to date of any progression events or last follow-up (up to 26 months)

  6. Time to next therapy (TTNT)

    Time frame: Through completion of follow-up (up to 26 months)

  7. Overall survival (OS)

    Overall survival is defined as the date of treatment start to date of death or date of last follow-up.

    Time frame: Start of treatment to death or last follow-up (up to 26 months)

07

Study locations

1 site
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    • Russell K Pachynski, M.D. · Contactrkpachynski@wustl.edu · 314-286-2341
    • Russell K Pachynski, M.D. · Principal investigator
    • Daniel Thorek, Ph.D. · Principal investigator
    • John Visconti, D.O. · Sub investigator
    • Melissa Reimers, M.D. · Sub investigator
    • Wilbur Song, M.D. · Sub investigator
    • Eric Knoche, M.D. · Sub investigator
    • Mark Sundermeyer, M.D. · Sub investigator
    • Peter Oppelt, M.D. · Sub investigator
    • Jingqin Rosy Luo, Ph.D. · Sub investigator
    • Jade Tao, Ph.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported will be available for investigators with approval by an independent review committee.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be made available beginning 9 months and ending 36 months following publication.

Access criteria: Investigators who have approval to use the data by an independent review committee.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2029, 28 months later.

Of 244 non-industry phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's planned 28 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2026
First posted
Aug 10, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Apr 14, 2029
CompletionEst.
Jan 31, 2031
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07756593
Collaborators
Dendreon, ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Apr 14, 2029 (estimated)
Completion
Jan 31, 2031 (estimated)
Last update
Aug 10, 2026

Study contacts

Russell K Pachynski, M.D.
Contact
rkpachynski@wustl.edu
314-286-2341
Russell K Pachynski, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nogapendekin alfa inbakicept

Start the discussion